Celsion Corp (CLSN) 1.22 $CLSN Celsion Corporation

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celsion Corp (CLSN) 1.22 $CLSN

Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Mon Aug 15, 8:00AM CDT
Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses
CLSN: 1.22 (-0.02)

Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer
GlobeNewswire - Mon Aug 15, 7:00AM CDT
Subgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox(R) plus Optimized RFA
CLSN: 1.22 (-0.02)

Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy
GlobeNewswire - Tue Aug 09, 8:00AM CDT
Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced today that it has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement (the "Agreement" with Zhejiang Hisun Pharmaceutical Co. Ltd. (SSE Code:600267), a leading pharmaceutical company in China, to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion's proprietary gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect. GEN-1 is currently being evaluated by Celsion in first line ovarian cancer patients.
CLSN: 1.22 (-0.02)

Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and six-month period ended June 30, 2016 and provide an update on its development programs for ThermoDox(R), its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, August 15, 2016. To participate in the call, interested parties may dial 1-877-723-9521 (Toll-Free/North America) or 1-719-325-4925 (International/Toll) and ask for the Celsion Corporation 2nd Quarter 2016 Earnings Call (Conference Code: 3335946) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
CLSN: 1.22 (-0.02)

Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting
PR Newswire - Tue May 24, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.22 (-0.02)

Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update
PR Newswire - Mon May 16, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA-based immunotherapy.
CLSN: 1.22 (-0.02)

Should You Buy Celsion (CLSN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:57AM CDT
Celsion (CLSN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
CLSN: 1.22 (-0.02)

Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016
PR Newswire - Mon May 09, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, May 16, 2016. To participate in the call, interested parties may dial 1-888-359-3624 (Toll-Free/North America) or 1-719-457-2085 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2016 Earnings Call (Conference Code: 7064110) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
CLSN: 1.22 (-0.02)

Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 23.94 (-0.25), CLSN: 1.22 (-0.02), JAZZ: 123.31 (-0.52)

ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Fri May 06, 7:14AM CDT
Our proven model does not conclusively show that ARIAD (ARIA) is likely to beat estimates this quarter given its Earnings ESP of 0.00% and Zacks Rank #5 (Strong Sell).
CLSN: 1.22 (-0.02), JAZZ: 123.31 (-0.52), ARIA: 10.19 (-0.15), CHMA: 2.46 (-0.01)

Penumbra (PEN): What Will Q1 Earnings Release Unveil?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:53AM CDT
Penumbra, Inc. (PEN) is expected to report its first-quarter 2016 financial numbers on May 9, after the market closes.
CLSN: 1.22 (-0.02), QSII: 11.78 (+0.01), PEN: 70.02 (-0.54), CHMA: 2.46 (-0.01)

Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study
PR Newswire - Mon May 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. In the first three patients dosed, GEN-1 plus standard chemotherapy produced excellent results, with no dose limiting toxicities and highly promising efficacy signals leading to successful surgical outcomes. The three patients were treated at the University of Alabama at Birmingham.
CLSN: 1.22 (-0.02)

Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China
PR Newswire - Tue Apr 26, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its ongoing global Phase III OPTIMA Study evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat newly diagnosed patients with primary liver cancer, also known as hepatocellular carcinoma (HCC).
CLSN: 1.22 (-0.02)

Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil®
PR Newswire - Tue Apr 19, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with Avastin® and Doxil® was presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site. The full poster presentation can be found on Celsion's website at www.celsion.com.
CLSN: 1.22 (-0.02)

Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer
PR Newswire - Tue Apr 12, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian cancer will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held in New Orleans from April 16-20, 2016. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
CLSN: 1.22 (-0.02)

Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update
PR Newswire - Wed Mar 30, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The Company's lead program is ThermoDox® which is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The Company's immunotherapy program consists of GEN-1 and is currently in Phase I development for the localized treatment of ovarian cancer.
CLSN: 1.22 (-0.02)

Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016
PR Newswire - Wed Mar 23, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Wednesday, March 30, 2016. To participate in the call, interested parties may dial 1-800-505-9587 (Toll-Free/North America) or 1-416-204-9524 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2015 Earnings Call (Conference Code: 4103364) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com.
CLSN: 1.22 (-0.02)

Global Peritoneal Cancer Therapeutics Pipeline Review H2 2015
M2 - Thu Jan 14, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dwpnp/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peritoneal Cancer Overview - Therapeutics Development - Pipeline Products for Peritoneal Cancer - Overview - Pipeline Products for Peritoneal Cancer - Comparative Analysis - Peritoneal Cancer - Therapeutics under Development by Companies - Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes - Peritoneal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peritoneal Cancer - Products under Development by Companies - Peritoneal Cancer - Products under Investigation by Universities/Institutes - Peritoneal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AbbVie Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Advanced Accelerator Applications SA - Amgen Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Atara Biotherapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Bayer AG - Beth Israel Deaconess Medical Center, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Celldex Therapeutics, Inc. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Corcept Therapeutics Incorporated - Critical Outcome Technologies Inc. - CritiTech, Inc. - CTI BioPharma Corp. - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Galena Biopharma, Inc. For more information visit http://www.researchandmarkets.com/research/9d...eal_cancer
CERU: 1.02 (unch), CLDX: 3.36 (+0.04), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), ATRA: 19.85 (+0.31), CTIC: 0.39 (unch), CLBS: 4.83 (-0.01), AAAP: 34.41 (-0.28), CLSN: 1.22 (-0.02), CLVS: 23.59 (-1.18), AZN: 32.60 (-0.21), AVEO: 0.91 (-0.02), GALE: 0.39 (-0.01), ABBV: 64.03 (-0.07), CORT: 5.35 (+0.02), EXEL: 11.35 (+0.20), XLRN: 30.25 (+0.24), ARRY: 3.52 (+0.09)

Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer
PR Newswire - Thu Jan 07, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant ovarian cancer. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The new data demonstrate that intraperitoneally-administered GEN-1 produces an immunologically distinct IL-12 protein that is localized at the tumor site and lasts for up to one week after a single treatment. Furthermore, concomitant increases in IFN- and TNF- a indicate that the IL-12 produced following treatment with GEN-1 treatment is immunologically active. Celsion Corporation is a fully integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases.
CLSN: 1.22 (-0.02)

Pulmonary Hypertension - Pipeline Review 2015
M2 - Wed Jan 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/6c3rcb/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Included: - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Complexa, Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Insmed Incorporated - Kowa Company, Ltd. - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - (20 Others) For more information visit http://www.researchandmarkets.com/research/6c3rcb/pulmonary
CYTK: 10.50 (-1.57), INSM: 13.39 (+0.44), CLSN: 1.22 (-0.02), ASND: 19.64 (+1.20), GILD: 77.42 (-0.96), LLY: 77.23 (-0.52), ARNA: 1.56 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading